RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
RadiusXR, Topcon Healthcare, and Glaukos (NYSE: GKOS) have announced a strategic collaboration and the launch of Inspire®, a next-generation wearable vision testing platform.
The partnership combines RadiusXR's innovative visual field technology, Topcon's robotic diagnostics expertise, and Glaukos' focus on democratizing ophthalmic disease diagnosis. Inspire is the first commercial wearable vision diagnostic system that integrates visual field testing with patient education and data-driven intelligence.
Under the agreement, Topcon Healthcare will become the exclusive global distributor of the Inspire platform. The six-ounce device is designed for future expansion beyond traditional diagnostics to support testing for other chronic and systemic conditions. The collaboration aims to expand patient access and enable doctors to provide visual field exams to all glaucoma patients requiring testing.
RadiusXR, Topcon Healthcare e Glaukos (NYSE: GKOS) hanno annunciato una collaborazione strategica e il lancio di Inspire®, una piattaforma di test visivi indossabile di nuova generazione.
La partnership combina la tecnologia innovativa del campo visivo di RadiusXR, l'expertise diagnostica robotica di Topcon e l'impegno di Glaukos nella democratizzazione della diagnosi delle malattie oftalmiche. Inspire è il primo sistema diagnostico visivo indossabile commerciale che integra il test del campo visivo con l'educazione del paziente e l'intelligenza basata sui dati.
In base all'accordo, Topcon Healthcare diventerà il distributore globale esclusivo della piattaforma Inspire. Il dispositivo di sei once è progettato per un'espansione futura oltre le diagnosi tradizionali, per supportare i test di altre condizioni croniche e sistemiche. La collaborazione mira ad ampliare l'accesso dei pazienti e a consentire ai medici di fornire esami del campo visivo a tutti i pazienti affetti da glaucoma che necessitano di test.
RadiusXR, Topcon Healthcare y Glaukos (NYSE: GKOS) han anunciado una colaboración estratégica y el lanzamiento de Inspire®, una plataforma de prueba de visión portátil de nueva generación.
La asociación combina la innovadora tecnología de campo visual de RadiusXR, la experiencia en diagnósticos robóticos de Topcon y el enfoque de Glaukos en democratizar el diagnóstico de enfermedades oftálmicas. Inspire es el primer sistema de diagnóstico visual portátil comercial que integra pruebas de campo visual con educación del paciente e inteligencia basada en datos.
Según el acuerdo, Topcon Healthcare se convertirá en el distribuidor global exclusivo de la plataforma Inspire. El dispositivo de seis onzas está diseñado para una futura expansión más allá de los diagnósticos tradicionales, para apoyar pruebas de otras condiciones crónicas y sistémicas. La colaboración tiene como objetivo ampliar el acceso de los pacientes y permitir que los médicos realicen exámenes de campo visual a todos los pacientes con glaucoma que requieran pruebas.
RadiusXR, Topcon Healthcare, 그리고 Glaukos (NYSE: GKOS)는 전략적 협력과 차세대 웨어러블 시력 검사 플랫폼인 Inspire®의 출시를 발표했습니다.
이 파트너십은 RadiusXR의 혁신적인 시야 기술, Topcon의 로봇 진단 전문성, Glaukos의 안과 질병 진단 민주화에 대한 초점을 결합합니다. Inspire는 시야 검사와 환자 교육 및 데이터 기반 지능을 통합한 최초의 상업용 웨어러블 시력 진단 시스템입니다.
계약에 따라 Topcon Healthcare는 Inspire 플랫폼의 독점 글로벌 유통업체가 됩니다. 6온스의 이 장치는 전통적인 진단을 넘어 다른 만성 및 전신 질환에 대한 검사를 지원하도록 설계되었습니다. 이 협력은 환자의 접근성을 확대하고 의사가 검사 필요한 모든 녹내장 환자에게 시야 검사를 제공할 수 있도록 하는 것을 목표로 합니다.
RadiusXR, Topcon Healthcare et Glaukos (NYSE: GKOS) ont annoncé une collaboration stratégique et le lancement de Inspire®, une plateforme de test de vision portable de nouvelle génération.
Ce partenariat combine la technologie innovante de champ visuel de RadiusXR, l'expertise en diagnostic robotique de Topcon et l'engagement de Glaukos à démocratiser le diagnostic des maladies ophtalmiques. Inspire est le premier système de diagnostic visuel portable commercial qui intègre les tests de champ visuel avec l'éducation des patients et l'intelligence basée sur les données.
Selon l'accord, Topcon Healthcare deviendra le distributeur mondial exclusif de la plateforme Inspire. L'appareil de six onces est conçu pour une future expansion au-delà des diagnostics traditionnels afin de soutenir les tests d'autres conditions chroniques et systémiques. La collaboration vise à élargir l'accès des patients et à permettre aux médecins de réaliser des examens de champ visuel pour tous les patients atteints de glaucome nécessitant des tests.
RadiusXR, Topcon Healthcare und Glaukos (NYSE: GKOS) haben eine strategische Zusammenarbeit und die Einführung von Inspire®, einer tragbaren Plattform zur Sehprüfung der nächsten Generation, angekündigt.
Die Partnerschaft kombiniert die innovative Technologie des Gesichtsfelds von RadiusXR, die robotergestützte Diagnosetechnologie von Topcon und Glaukos' Fokus auf die Demokratisierung der Diagnose von Augenkrankheiten. Inspire ist das erste kommerzielle tragbare Sehdiagnosesystem, das Gesichtsfeldtests mit Patientenaufklärung und datengestützter Intelligenz integriert.
Gemäß der Vereinbarung wird Topcon Healthcare der exklusive globale Vertriebspartner der Inspire-Plattform. Das sechs Unzen schwere Gerät ist für eine zukünftige Erweiterung über traditionelle Diagnosen hinaus konzipiert, um Tests für andere chronische und systemische Erkrankungen zu unterstützen. Die Zusammenarbeit zielt darauf ab, den Zugang für Patienten zu erweitern und Ärzten zu ermöglichen, Gesichtsfelduntersuchungen für alle Glaukompatienten, die eine Prüfung benötigen, durchzuführen.
- Strategic partnership expands GKOS's market reach through Topcon's global distribution network
- New revenue stream potential through innovative diagnostic technology
- Strengthens GKOS's position in glaucoma care market
- None.
Insights
This three-way collaboration between Glaukos, RadiusXR, and Topcon Healthcare represents a strategic expansion of Glaukos' ecosystem in the glaucoma care continuum. By partnering with Topcon, a global leader in ophthalmic diagnostics with established distribution channels, Glaukos gains access to a significantly expanded commercial footprint for implementing this innovative diagnostic technology.
The Inspire platform addresses a critical market gap: while visual field testing is essential for glaucoma management, access limitations and traditional testing constraints have hampered widespread adoption. By embracing a wearable, lightweight (six-ounce) technology that correlates with clinical standards, Glaukos is positioning itself at the intersection of diagnostics and therapeutics.
From a business strategy perspective, this move reflects Glaukos' evolution from a single-product company to an integrated glaucoma solution provider. The diagnostic-therapeutic feedback loop creates potential synergies - more accessible testing leads to earlier diagnosis, potentially expanding the patient pool for Glaukos' treatment options.
While financial terms remain undisclosed, the long-term value proposition is compelling. The platform's design for "future expansion" beyond ophthalmic applications suggests additional revenue opportunities across other chronic conditions. Furthermore, the data-driven intelligence component aligns with growing healthcare demands for evidence-based decision support.
This partnership effectively strengthens Glaukos' competitive positioning against both traditional diagnostic equipment manufacturers and therapeutic-only companies by creating an integrated approach to patient care. The exclusive global distribution agreement with Topcon provides a clear commercialization pathway that should accelerate market penetration beyond what Glaukos could achieve independently.
The Inspire platform introduces a paradigm shift in visual field testing through its wearable form factor. Traditional perimetry typically requires bulky, immobile equipment that limits testing to specialized facilities with trained technicians. By engineering this capability into a six-ounce wearable device that correlates to clinical standards, the technology fundamentally transforms accessibility patterns for this essential diagnostic.
What distinguishes this platform technologically is its multi-dimensional functionality. Beyond basic testing, the system incorporates:
- Onboard patient education capabilities, addressing the knowledge gap that often impedes effective glaucoma management
- Data-driven intelligence to support clinical decision-making
- Integration with Topcon's Harmony digital health platform, creating data continuity across the diagnostic ecosystem
The platform's architecture appears designed for extensibility, with the article noting it's "purpose-built for future expansion" beyond traditional diagnostics to "support testing for other chronic and systemic conditions." This suggests a modular technical framework that could accommodate additional testing protocols through software updates rather than hardware replacements.
From a clinical impact perspective, visual field testing represents a critical diagnostic bottleneck in glaucoma management. Despite being essential for disease monitoring, logistical barriers often result in patients missing recommended tests. By potentially enabling testing in more diverse settings, this technology addresses a documented care gap in the glaucoma management pathway.
The integration of this wearable technology with Topcon's robotic diagnostics and Harmony platform creates a technically sophisticated data ecosystem that could enable more comprehensive patient assessment through multi-modal data synthesis - a technological advantage over stand-alone diagnostic systems.
Industry Leaders Partner to Advance Vision Testing and Digital Solutions to Expand Patient Access to Eye Care Globally
Inspire by RadiusXR is the only commercially available wearable vision diagnostic system that combines visual field testing correlated to the clinical standard with proven performance, onboard patient education, and data-driven intelligence to support more informed clinical decisions. Six ounces and purpose-built for future expansion, Inspire extends beyond traditional diagnostics to support testing for other chronic and systemic conditions.
“The collaboration between RadiusXR, Topcon Healthcare, and Glaukos combines the experience and commitment of like-minded individuals with innovative diagnostic and therapeutic solutions to accelerate the transformation of healthcare towards a more integrated, personalized approach for diagnosis and treatment,” said Ali Tafreshi, CEO and President of Topcon Healthcare, Inc. “By intelligently combining data from the new Inspire wearable vision testing platform with our robotic diagnostics on the Harmony digital health information platform, we are furthering our Healthcare from the Eye initiative with a truly dynamic digital healthcare ecosystem.”
The addition of the RadiusXR Inspire wearable visual field technology to Topcon Healthcare’s portfolio will streamline vision testing and make it more accessible for patients globally. Under this partnership, Topcon Healthcare will become the exclusive global distributor of the Inspire platform and will work with RadiusXR and Glaukos to expand the wearable diagnostic footprint through collaboration on commercialization efforts, research, and education. Additionally, Glaukos and Topcon Healthcare will work closely to advance patient engagement, education, and the digital eyecare ecosystem.
“We are pleased to partner with Topcon Healthcare to strengthen commercialization efforts for the RadiusXR technology and expand patient access to the Inspire platform,” said Thomas Burns, Chairman and CEO of Glaukos. “This collaboration aligns with our mission to meaningfully advance the standard of care in glaucoma and improve outcomes by democratizing visual field testing and access to the digital tools needed to enable effective patient care worldwide.”
The launch of Inspire is a powerful collaboration between RadiusXR, Topcon Healthcare, and Glaukos, leveraging each company’s expertise to accelerate advancement of vision diagnostics. By integrating wearable vision testing with comprehensive ophthalmic imaging and AI-driven data analysis, the three companies aim to expand access to high-quality eye care, enabling earlier disease detection, and driving smarter diagnostics.
“RadiusXR was founded with the mission of transforming digital health through innovation, and the launch of Inspire is a testament to that commitment,” said Ammad Khan, CEO of RadiusXR. “By integrating our advanced wearable platform with Topcon Healthcare’s imaging solutions and Glaukos’ focus on patient engagement, we are delivering a truly connected and accessible diagnostic ecosystem that empowers clinicians and expands access to critical vision care.”
About Topcon Healthcare: Topcon Healthcare, Inc. is part of Topcon Corporation. We are a leading provider of digital healthcare solutions whose vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, the strategy of applying AI models to imaging data from the eye to facilitate earlier detection and better management of disease. Healthcare from the Eye is powered by Harmony®, a cloud-based, vendor-inclusive digital health information platform enabling a connected care ecosystem.
About RadiusXR: RadiusXR is a digital healthcare technology company with a passion for solving complex healthcare issues. We focus on transforming vision testing and eye care with an advanced digital platform that enables unrivaled patient access, streamlines operations, and creates more confidence at the point of care. With our advanced wearable technologies, we continue developing disruptive technologies that challenge the healthcare status quo. For more information, visit www.radiusxr.com.
About Glaukos: Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the extent to which we can make vision testing more accessible and improve outcomes by expanding patient access and enabling doctors to provide visual field exams and education to
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311974567/en/
Media Contact
Andria Arena
aarena@jpa.com
Investor Contact:
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
What is the Inspire® wearable vision testing platform launched by RadiusXR and GKOS?
How will the RadiusXR and GKOS partnership with Topcon Healthcare affect distribution?
What are the key features of the Inspire® platform developed by GKOS and partners?
What is the main goal of the GKOS collaboration with RadiusXR and Topcon?
